PF 3932295Alternative Names: PF-3932295
Latest Information Update: 20 Apr 2009
At a glance
- Originator Pfizer
- Class Obesity therapies
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 31 Mar 2009 Discontinued - Phase-I for Obesity in USA (unspecified route)
- 30 Sep 2008 Phase-I clinical trials in Obesity in USA (unspecified route)